Radius Health

AntriaBio

Corcept Therapeutics

Crinetics Pharmaceuticals

Spruce Biosciences

MannKind Corporation

406 PubMed publications found for Radius Health

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.

Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial.

Integrated computational and structural understanding of Prunus bokharensis-derived β-Glucan: HRMS, network pharmacology, docking, and MD simulations to discover multi-target interactions for immunomodulation, antimelanoma lipid-hormone axis modulation, and erythroprotection.

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial.

OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer.

404 PubMed publications found for Radius Health

Predictive value of BMD for hip and other fractures: a meta-analysis to update FRAX.

407 PubMed publications found for Radius Health

SW convergence: 50/100 (Neutral), 1 bullish / 0 bearish signals

403 PubMed publications found for Radius Health

The effects of abaloparatide on acetabular bone mineral density and proximal femur strength in men with osteoporosis.

402 PubMed publications found for Radius Health

A meta-analysis of smoking and fracture risk to update the FRAX® tool.

405 PubMed publications found for Radius Health

401 PubMed publications found for Radius Health

The effects of marine fatty acid omega-3 supplements on incident fractures and bone mineral density in generally healthy adults.

L-Relationship between uncertainty and average seizure frequency in clinical trials of antiseizure medications.

<article class="bts-verified-summary" data-ticker="RDUS">
<p>Radius Health (RDUS) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.</p>
<p>No Form 4 insider filings for RDUS were recorded at the SEC in the past 30 days<sup><a href="#fn-1">[1]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">SEC EDGAR (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22RDUS%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

SEC EDGAR

Radius Health (RDUS) — BioTechSigns Verified Summary

Radius Health (RDUS) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.

No Form 4 insider filings for RDUS were recorded at the SEC in the past 30 days[1].

Sources:
[1] SEC EDGAR. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://efts.sec.gov/LATEST/search-index?q=%22RDUS%22&forms=4&dateRange=custom&startdt=2026-03-12&enddt=2026-04-11